MedTrace Logo

A Study of CCX140-B in Subjects With FSGS

NCT03536754 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-03-13

Study results available
· View outcomes & findings →

Summary

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia

Conditions

  • FSGS
  • Focal Segmental Glomerulosclerosis
  • Glomerulosclerosis

Interventions

OTHER

Placebo

Three placebo tablets, taken twice daily (BID), per os, for 84 days (12 weeks)

DRUG

CCX140-B

One 5 mg CCX140-B tablet and 2 placebo tablets in the morning; 3 placebo tablets in the evening; per os, for 84 days.

DRUG

CCX140-B

Two 5 mg CCX140-B tablets and 1 placebo tablet, taken BID; per os, for 84 days.

DRUG

CCX140-B

Three 5 mg CCX140-B tablets, taken BID; per os, for 84 days.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-17
Primary Completion
2020-02-19
Completion
2020-02-19
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • France
  • Italy
  • New Zealand
  • Poland
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03536754 on ClinicalTrials.gov